Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Taro Says Its Special Committee Of Board Rejects Proposal From Sun Pharma

RELATED NEWS
Trade TARO now with 

Taro Pharmaceutical Industries Ltd. (TARO: Quote) announced that the Special Committee of its Board of Directors unanimously rejected the October 18, 2011 unsolicited, non-binding offer from Sun Pharmaceutical Industries Ltd. to buy all of the issued and outstanding shares of Taro not currently held by Sun Pharma for $24.50 per share as inadequate and not in the best interests of Taro's minority shareholders.

Taro noted that the Special Committee reached its conclusion after careful consideration, including a thorough review of Taro's business and prospects with its independent financial advisor Citigroup Global Markets Inc. and its independent legal counsel Goldfarb Seligman & Co. as its Israeli legal counsel and Willkie Farr & Gallagher LLP, as its US legal counsel.

Click here to receive FREE breaking news email alerts for Taro Pharmaceutical Industries Ltd and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After ending the previous session nearly flat, stocks moved mostly lower over the course of the trading day on Friday. Uncertainty about the outlook for monetary policy weighed on the markets ahead of next week's Federal Reserve meeting. Despite the ceasefire in eastern Ukraine, the U.S. Treasury Department on Friday announced a new round of sanctions against Russia for its role in the conflict. Treasury Secretary Jacob Lew determined that persons operating within Russia's defense and related materiel sector may now be subject to targeted sanctions. Business inventories in the U.S increased in line with economist estimates in the month of July, according to a report released by the Commerce Department on Friday. The Commerce Department said business inventories rose by 0.4 percent in July, matching the increase reported for June as well as the consensus estimate.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.